Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

Texas MPN Workshop 2022 | Interferon in polycythemia vera: long – term experience from a single center

Richard Silver • 10 Nov 2022
Texas MPN Workshop 2022
Essential Thrombocythemia Myelofibrosis Myeloproliferative Neoplasms Polycythemia Vera Rare Diseases Interferon Ropeginterferon alfa-2a Ropeginterferon alfa-2b

Richard Silver, MD, Weill Cornell Medical College, New York, NY, gives a presentation on the long-term outcomes of interferon use in polycythemia vera (PV) at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

More from Richard Silver

The role of rusfertide in polycythemia vera 3:23
The role of rusfertide in polycythemia vera
Richard Silver • 18 Oct 2022
The role of interferon in polycythemia vera & perspectives on the management of low-risk patients 6:49
The role of interferon in polycythemia vera & perspectives on the management of low-risk patients
Richard Silver • 18 Oct 2022
Management of patients with PV who are intolerant to interferon and who develop post-polycythemic MF 6:19
Management of patients with PV who are intolerant to interferon and who develop post-polycythemic MF
Richard Silver • 18 Oct 2022
Looking forward to the 2022 MPN Congress 2:50
Looking forward to the 2022 MPN Congress
Richard Silver • 18 Oct 2022

Related Videos

Targeting CALR mutations in MPNs: a promising novel immunotherapeutic approach 2:14
Targeting CALR mutations in MPNs: a promising novel immunotherapeutic approach
John Mascarenhas • 4 Sep 2025
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors 1:19
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors
John Mascarenhas • 3 Sep 2025
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS 10:06
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS
Asfand Yar Cheema • 5 Sep 2025
The value of fedratinib for the treatment of patients with MF in the second-line setting 1:19
The value of fedratinib for the treatment of patients with MF in the second-line setting
Francesco Passamonti • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals